CAS 1227948-02-8

BI-4464

CAS : 1227948-02-8

3-Methoxy-N-(1-methylpiperidin-4-yl)-4-((4-((3-oxo-2,3-dihydro-1H-inden-4-yl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide

Formule : C₂₈H₂₈F₃N₅O₄

Degré de pureté : 98%

Masse moléculaire : 555.55

Ref: IN-DG01141864

BI-4464

CAS : 1227948-02-8

Formule : C₂₈H₂₈F₃N₅O₄

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 555.5482

Ref: IN-DA01MVJR

BI-4464

CAS : 1227948-02-8

BI-4464

Formule : C₂₈H₂₈F₃N₅O₄

Degré de pureté : ≥95%

Masse moléculaire : 555.55

Ref: 54-BUP01581

BI-4464

CAS : 1227948-02-8

BI-4464 is a highly selective ATP competitive inhibitor of PTK2/FAK, with an IC50 of 17 nM. A PTK2 ligand for PROTAC

Formule : C₂₈H₂₈F₃N₅O₄

Degré de pureté : 99.81%

Couleur et forme : Solid

Masse moléculaire : 555.55

Ref: TM-T5480

BI-4464

CAS : 1227948-02-8

Degré de pureté : 98%

Masse moléculaire : 555.56

Ref: 10-F840892

BI-4464

CAS : 1227948-02-8

BI-4464 is a novel anti-inflammatory agent that has been shown to have a potential beneficial effect on acute ischemic stroke. It has been shown to decrease the size of the infarcted area and improve neurologic function in animal models of stroke. BI-4464 binds to matrix metalloproteinases, which are enzymes involved in inflammation, and prevents them from degrading extracellular matrix proteins. These proteinases are also thought to be involved in the pathogenesis of acute ischemic stroke by breaking down blood vessels. BI-4464 also inhibits DNA polymerase activity, leading to reduced levels of DNA synthesis and cell death. BI-4464 has not yet been tested in humans but is currently being evaluated in clinical trials for safety and efficacy as an anti-inflammatory agent.

Formule : C₂₈H₂₈F₃N₅O₄

Degré de pureté : Min. 95%

Masse moléculaire : 555.55 g/mol

Ref: 3D-CZB94802